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Abstract Transplantation of human embryonic stem cell-
derived cardiomyocytes (hESC-CM) for cardiac regenera-
tion is hampered by the formation of fibrotic tissue around
the grafts, preventing electrophysiological coupling. Inves-
tigating this process, we found that: (1) beating hESC-CM in
vitro are embedded in collagens, laminin and fibronectin,
which they bind via appropriate integrins; (2) after trans-
plantation into the mouse heart, hESC-CM continue to
secrete collagen IV, XVIII and fibronectin; (3) integrin
expression on hESC-CM largely matches the matrix type
they encounter or secrete in vivo; (4) co-transplantation of
hESC-derived endothelial cells and/or cardiac progenitors
with hESC-CM results in the formation of functional cap-
illaries; and (5) transplanted hESC-CM survive and mature
in vivo for at least 24 weeks. These results form the basis of
future developments aiming to reduce the adverse fibrotic
reaction that currently complicates cell-based therapies for
cardiac disease, and to provide an additional clue towards
successful engraftment of cardiomyocytes by co-trans-
planting endothelial cells.
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Introduction
Heart failure is one of the most prevalent causes of mor-
bidity and mortality worldwide and is most commonly due
to loss of cardiomyocytes after myocardial infarction (MI)
[1]. Until recently, loss of viable cardiomyocytes was
considered irreversible since the adult mammalian myo-
cardium lacks the ability to regenerate. However, with the
discovery of stem cells with the capacity to differentiate
into cardiomyocytes and other cardiac cells, it may be
possible to replenish the diseased heart with new myocar-
dium [2, 3]. Human embryonic stem cells (hESC) are one
source that holds promise in this respect, since they can
proliferate indefinitely in culture and differentiate into
cardiomyocytes with acceptable efficiencies [4–6], thus
providing a potential source of cells for both chronic and
acute applications. However, aside from their ethical sen-
sitivity, several scientific issues need to be addressed
before clinical application becomes feasible. Questions
have emerged from studies on the engraftment of
hESC-derived cardiomyocytes (hESC-CM) in uninjured,
infarcted, and arrhythmic hearts of experimental animals
[5, 7–11]. These issues concern primarily integration, sur-
vival, safety, immunogenicity and ability to contribute
to long-term contractile function. When hESC-CM were
transplanted into electrophysiologically silenced guinea pig
and swine hearts, they acted as biological pacemakers for
Electronic supplementary material The online version of this
article (doi:10.1007/s00018-009-0179-z) contains supplementary
material, which is available to authorized users.
L. W. van Laake  P. A. Doevendans
Heart Lung Center Utrecht, Utrecht, The Netherlands
E. G. van Donselaar  B. M. Humbel  A. J. Verkleij
Cellular Architecture and Dynamics, Faculty of Sciences,
Utrecht University, Utrecht, The Netherlands
J. Monshouwer-Kloots  C. Schreurs  R. Passier 
C. L. Mummery (&)
Department of Anatomy and Embryology, Leiden University
Medical Center, Postal zone: S-1-P, P.O. Box 9600,
2300 RC Leiden, The Netherlands
e-mail: c.l.mummery@lumc.nl
A. Sonnenberg
The Netherlands Cancer Institute, Amsterdam, The Netherlands
Cell. Mol. Life Sci. (2010) 67:277–290
DOI 10.1007/s00018-009-0179-z Cellular and Molecular Life Sciences
the recipient myocardium [8, 11]. This indicated that donor
hESC-CM can couple functionally to host cardiomyocytes,
which is a prerequisite for a safe and effective outcome of
such cell-based therapies. On the other hand, in studies
where histological results were extensively analyzed, grafts
consisting of hESC-CM were found to be largely isolated
from the host myocardium by extracellular matrix both in
infarcted and non-infarcted hearts [5, 7, 9, 10]. While
extracellular matrix provides a structural, chemical, and
mechanical substrate that is essential for development and
responses to pathophysiological signals [12], inappropriate
or excessive secretion may have adverse effects. It could,
for example, lead to separation of donor from host
cardiomyocytes. Although this would not necessarily
exclude functional coupling completely, since electro-
physiological signaling can be conducted through
relatively thick layers of fibrotic tissue [13], it could
increase the risk of arrhythmias [14] especially in larger
animals and humans if a similar fibrotic layer developed.
Additionally, impaired coupling of donor and host cells
may in part explain why cell transplantation has been more
successful in improving short- and mid-term cardiac
function after MI than in providing sustained long-term
functional improvement [10, 15]. It would therefore be
useful to determine the characteristics and origin of the
fibrotic tissue surrounding hESC-CM grafts, so that strat-
egies aimed at reducing matrix deposition could be
developed. Encapsulation of the graft can be seen as simply
a reaction of the host to exogenous cells, but another
possibility is that hESC-derived cells produce their own
extracellular matrix to create a more suitable local envi-
ronment, or niche. It is not thought that the fibrotic layer is
merely the result of mouse reaction to human tissue since
encapsulation also occurs in transplantations from mouse
to mouse [16].
The capacity of cells to attach to and thrive in a
particular matrix depends on the expression of integrins,
heterodimeric transmembrane receptors composed of
a- and b-subunits, at their cell surface. Individual cells may
express multiple integrins, which allow them to interact
with multiple extracellular matrix ligands [12]. The inte-
grin expression pattern of hESC-CM is currently unknown,
but would be useful for understanding mechanisms avail-
able for anchoring in recipient heart tissue and how they
modulate their own environment to create an optimal niche
for survival and integration. In addition, it may shed light
on the selective survival of hESC-CM in the heart com-
pared to other cell types [9, 10]. In a recent study, we
detected a dense fibrotic layer around hESC-CM grafts at
the electron-microscopic (EM) level 12 weeks after trans-
plantation [10]. It is presently unknown when fibrosis
develops, when it reaches a maximum, and how long
grafted cells are under suboptimal conditions. If excessive
extracellular matrix formation is a late reaction, graft sur-
vival may not significantly exceed 12 weeks, the longest
follow-up time reported so far. Alternatively, compensa-
tory mechanisms may develop that support graft survival,
for example neovascularization through the fibrotic layer.
Here, we address these questions by analyzing healthy
and infarcted mouse hearts at several time-points after
intramyocardial transplantation of hESC-CM, with a fol-
low-up to 24 weeks. We determined the composition of the
extracellular matrix surrounding the grafts with respect to
matrix type and origin. In addition, we characterized the
integrin expression of hESC-CM in vitro before trans-
plantation and at various time-points thereafter. We also
carried out an extensive EM study using immunogold
labeling of GFP to identify the genetically marked human
cells and monitor their behavior in the graft over time.
Materials and methods
Cell culture, differentiation and dissociation
HES3-GFP cells [17] were co-cultured with END2 cells to
induce cardiomyocyte differentiation [6, 18]. Large num-
bers of beating areas were obtained within 12 days that
consisted of 20–25% cardiomyocytes and 75–80% endo-
dermal or other mesodermal derivates [6, 19]. Beating
areas were dissected and dissociated with collagenase A
(Roche, Cat. No. 11 088 858 001) as previously described
[6, 20, 21]. One million cells were taken up in a final
volume of 5 ll of fresh culture medium (DMEM ? 20%
FCS) and used for transplantation. For immunofluorescent
staining, beating areas were isolated, fixed and processed
for cryosections as described [21] or for electron micros-
copy (see below).
Animals and surgical procedures
The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996) and in line with the ‘Ethical principles and guide-
lines for scientific experiments on animals’ of the Swiss
Academy of Medical Sciences, and was approved by the
Institute Animal Care Committee. Male NOD-SCID mice
(Charles River) of 12 weeks of age were used (n = 32; 4–6
per time-point per condition). MI was induced under
isoflurane anesthesia by ligation of the left anterior
descending coronary artery (LAD) as described [21]. The
surgical procedure for non-infarcted mice was identical but
without ligation of the LAD. In the same operation, cells
were injected in the infarcted or healthy myocardium of the
free left ventricular wall using an insulin syringe with
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incorporated 29G needle. At 2 days, and 4, 12, and
24 weeks after surgery, animals were euthanized and the
hearts were fixed and processed either for cryosections as
described [21] or for electron microscopy (see below).
Human fetal heart tissue
The investigation conforms to the principles outlined in the
Declaration of Helsinki. Human fetal hearts were obtained
after elective abortion and with informed consent after
approval by the Institutional Ethics Committee.
Immunofluorescence and confocal microscopy
The entire region containing GFP-expressing cells of each
heart was cut into 6-lm cryosections, which were stained
as described [21, 22] (antibodies and dilutions are in the
electronic supplementary material, ESM). Isotype-matched
controls were performed for all antibodies.
Confocal laser scanning microscopy (sequential scan-
ning for DAPI and Alexa 405 with excitation laser 405 nm,
GFP with 488 nm, Cy3 with 532 nm and Cy5 with
633 nm) was performed on a Leica TCS SPE confocal with
DMI4000B microscope using LAS-AF software. Cell
software (Olympus) was used to quantify the amount of
matrix, comparing different time-points (note: matrix types
cannot be quantified in absolute numbers due to differential
affinity of the antibodies). Investigators were blinded for
time-point and matrix or integrin type scoring.
Immunogold labeling and electron microscopy
Hearts were perfusion—and subsequently immersion—
fixed with 2% formaldehyde/0.05% glutaraldehyde in
100 mM phosphate buffer pH 7.4, and processed for
Tokuyasu cryo-sectioning [23, 24]. Colonies of hESCs or
beating areas were immersion-fixed with the same fixa-
tives. 60 nm sections were labeled with antibodies against
GFP (1:100) (rabbit; Abcam), cytokeratin 8 (troma-1) (1:3)
(rat; Developmental Studies Hybridoma Bank), Tra-1-60
(1:60) (mouse; Chemicon), and human von Willebrand
Factor (1:300) (mouse; clone CLB-RAg 38, a kind gift
from Prof. P.H. de Groot). Isotype-matched controls were
performed for each antibody. Primary antibodies were
detected with protein A 10 or 15 nm gold (Utrecht Medical
Center, Cell Microscopy Center) [25], and imaged with a
JEOL 1010 electron microscope at 80 kV.
Results
The development of extracellular matrix around hESC-CM
grafts over time is summarized in Table 1 and quantified in
ESM Fig. 3. We first determined the matrix proteins
present in isolated beating areas of hES3-GFP at the 12-day
time-point when transplantation normally took place.
Cardiomyocytes in beating areas were surrounded by col-
lagen I, collagen IV, collagen XVIII, total laminin
including laminin 1, 8, 10 and other isoforms, and fibro-
nectin (Fig. 1a–e), but laminin-211 was absent. These
matrix components are all normally present in the mam-
malian myocardium, where collagen I is secreted by
fibroblasts, collagen IV by cardiomyocytes, and laminin
and fibronectin by both [26]. Collagen XVIII is present in
the adult heart only in blood vessels [27], but we found it to
be highly expressed throughout the human fetal myocar-
dium until 16 weeks of gestation (ESM Fig. 1). HESC-CM
expressed one or more integrins that enabled binding to
each matrix type (Fig. 1f–m): a11 for collagen, little a3
and a6 for laminin (in addition a7 was expressed at the
RNA level; no antibody was available) (ESM Fig. 2), a5
and aV for fibronectin and fibronectin/vitronectin, respec-
tively, and integrin b1 that can heterodimerize with all of
these a subunits.
We then analyzed grafts, identified by GFP-fluorescence
as previously [10], 2 days, and 4 and 12 weeks after
transplantation in non-infarcted hearts of NOD-SCID mice.
From 4 weeks onwards, these grafts consisted almost
exclusively of cardiomyocytes due to their preferential
survival, as described [10, 28]. At all time-points, collagen
I was expressed homogeneously throughout the myo-
cardium and in the scar tissue resulting from the
intramyocardial injection (Fig. 2a–b). However, at 4 and
12 weeks, excessive quantities of collagen I encapsulated
most of the grafted cells (Fig. 2b). This over-secretion may
be host-derived since collagen I is secreted by fibroblasts
and not cardiomyocytes, and no human fibroblasts were
found in the mouse heart despite an extensive search using
EM. Using human-specific antibodies, human collagen
IV and human collagen XVIII were identified around
hESC-CM at all time-points (Fig. 2c–f). Moreover, at 4
and 12 weeks after transplantation, patches of human col-
lagen IV and XVIII were also present at some distance
from the grafts. Thus, hESC-CM secreted substantial
amounts of collagen IV and XVIII in vivo in the mouse
heart. Laminin also enveloped hESC-CM at all time-points
but not excessively (Fig. 2g, h). Laminin-211 was absent in
grafts 2 days post-transplantation, but became expressed
thereafter in the same moderate quantities as laminin
(Fig. 2i, j). Thus, laminins may be donor- and/or host-
derived, but do not contribute significantly to the fibrotic
tissue separating donor from host cells. Fibronectin filled
the graft area abundantly 2 days after transplantation but
this decreased over time (Fig. 2k, l). Human fibronectin
was less prevalent by 4 weeks after transplantation, while
mouse fibronectin was reduced by 12 weeks. Taken
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together, the results show that hESC-CM secrete fibro-
nectin which is downregulated after transplantation in the
non-infarcted heart. Secretion of mouse fibronectin, on the
other hand, appears to be a response to the cell transplan-
tation but is eventually resolved.
Analysis of the integrin expression of hESC-CM in vivo
indicated that these cells bind collagens via integrin a11 at
all time-points, just as in vitro (Fig. 3a and Table 1).
Laminin-binding integrin a3 was upregulated in vivo,
while a6 was slightly downregulated (Fig. 3c, e and
Table 1). Integrins a5 and aV, which bind fibronectin and
fibronectin/vitronectin, respectively, were reduced over
time (Fig. 3b, d and Table 1). Integrin b1 expression
remained high at all time-points (Fig. 3f and Table 1).
We next investigated whether myocardial infarction
triggered a different extracellular matrix response to and by
hESC-CM grafts by injecting hESC-CM into acutely
infarcted mouse myocardium. At 4 and 12 weeks post-
operatively, collagen I was a major matrix component of
the infarct area and was extensively present around the
hESC-CM grafts, as in grafts in non-infarcted hearts
(Fig. 4a). Human collagen IV and XVIII were again
secreted by hESC-CM, with collagen XVIII in larger
quantities than in non-infarcted hearts (Fig. 4c–f). Laminin
Fig. 1 Extracellular matrix and integrin expression in beating areas
from hESCs. a–e hESC-CM from hES3-GFP are surrounded by
collagen I, collagen IV, collagen XVIII, laminin and fibronectin
(GFP not shown for clarity). f–m hESC-CM express collagen receptor
integrin a11, some laminin receptors a3 and a6, fibronectin/
vitronectin receptors integrin a5 and aV, and the common b-subunit
integrin b1. TnI and a-act cardiomyocyte markers troponin I or
a-actinin, green GFP, blue DAPI. Scale bars 20 lm
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contributed significantly to the infarct area but laminin-211
to a lesser extent (Fig. 4b, g, h); neither increased in
relation to the transplanted hESC-CM. Fibronectin was
abundant in the infarct zone; in areas with hESC-CM
grafts, this included human fibronectin (Fig. 4i, j). Unlike
in the non-infarcted heart, the human fibronectin content
was still high even at 12 weeks after transplantation.
Integrin expression was similar to that of hESC-CM in
non-infarcted hearts.
Since fibrosis was present at early time-points and was
not degraded 12 weeks post-grafting, the question arose
whether transplanted hESC-CM could survive at all for
longer periods. We therefore increased follow-up to
24 weeks and found viable grafts that appeared similar to
those at 12 weeks in terms of graft size and GFP-fluores-
cence. At both time-points, the hESC-CM showed signs of
maturation in vivo, including loss of punctuate staining for
cytokeratin 8 which was found in intracellular keratin
threads and desmosomes in immature hESC-CM in vitro
(Fig. 5a, b), as previously reported for human fetal
cardiomyocytes [29]. However, EM analysis of the grafted
cells 24 weeks after transplantation revealed that the
hESC-CM had matured further, evidenced by increased
myofibril content and improved sarcomeric organization
compared to 12 weeks in vivo maturation (Fig. 5c, d).
Paradoxically, a fibrotic layer surrounding the graft still
largely separated human from mouse myocardium, pre-
venting desmosome formation between human and mouse
cells (Fig. 5e) even though desmosomes between human
cardiomyocytes were abundant (Fig. 5d). It was thus likely
that the grafts received oxygen and nutrients through
infiltrating vessels. We observed previously that some
mouse-derived vessels were present in the grafts [10].
Surprisingly, a subset of 12- and 24-week hESC-CM grafts
(4 out of 16 hearts) were surrounded by small clusters of
GFP-expressing cells which formed a mosaic-like pattern
with the native mouse cardiomyocytes (Figs. 5f and 6a).
The morphology of these hESC-derived cells was typical
of endothelial cells: long flat cells aligning into capillaries
(Fig. 6d) with the typical appearance of caveolae and
Weibel-palade bodies. The capillaries consisted uniquely
of GFP-expressing human endothelial cells but were con-
nected to the mouse vasculature, as evidenced by the
presence of mouse leukocytes and erythrocytes in their
lumen (Fig. 6b, c), and were associated with an increased
vascular density in the area around the grafts.
We next sought to distinguish whether the observed
endothelial cells were formed from in vivo differentiation
of hESCs or supplementary co-injection of in vitro dif-
ferentiated hESCs into endothelial cells. We found that
some hESC-derived beating areas, the starting material
for transplantations, contained tube-like structures that
expressed human von Willebrand factor and human
PECAM-1 (CD31) (Fig. 6e). Donor-derived neovascu-
larization was thus most likely a result of the
supplementary co-injection of hESC-endothelial cells
(hESC-EC) with hESC-CM, although there may have
been bipotent cardiac progenitors present as many of the
cells expressed Isl1 [6, 30]. In addition, a proportion of
the hESC-EC population was still proliferating both in
vitro and in vivo (Fig. 6f–h).
To exclude the possibility that undifferentiated hESCs
were unintentionally co-transplanted and subsequently
contributed to neovascularization, we analyzed hESC ultra-
structural characteristics and compared these with grafted
cells and beating areas. We found no similarities in the
ultra-structure of GFP-cells in beating areas or in grafts at
any time-point with undifferentiated hESCs. Unlike dif-
ferentiated hESCs, undifferentiated hESCs showed strong
immunoreactivity with the stem cell marker Tra-1-60 on
their apical side and in the endocytotic and biosynthetic
systems (Fig. 6i, j). Thus, formation of hESC-derived
capillaries was from co-injected hESC-EC, not from
undifferentiated hESCs.
Discussion
This is the first study to date characterizing the fibrotic
response after intramyocardial cell transplantation,
describing the integrin expression profile of hESC-CM, and
documenting neovascularization following co-transplanta-
tion of hESC-CM and hESC-EC into the mouse heart. The
key findings can be summarized as follows.
1. hESC-CM in beating areas in vitro are embedded in
collagen I, IV and XVIII, laminin, and fibronectin, all
of which they can bind via appropriate integrins.
2. After transplantation into immunodeficient mouse
hearts, hESC-CM continue to secrete extracellular
matrix, in particular collagen IV and XVIII and to a
lesser extent fibronectin, while host fibroblasts may
contribute to encapsulation of the graft by secreting
collagen I. The donor cell contribution of fibronectin
and collagen XVIII is increased after transplantation
into infarcted hearts.
Fig. 2 hESC-CM secrete extracellular matrix and evoke excessive
matrix production by host cells after intramyocardial transplantation.
a–b Large amounts of collagen I surrounding grafts 2 days and
12 weeks after transplantation. c–d Human collagen IV in the
immediate proximity of hESC-CM. e–f Human collagen XVIII in the
immediate proximity of hESC-CM. g–h Laminin envelops hESC-CM
in similar amounts as host cardiomyocytes. i–j Laminin-211 is
increasingly present around transplanted hESC-CM and eventually in
similar amounts as host cardiomyocytes. k–l hESC-CM secrete
fibronectin at early time-points after transplantation, but this is
reduced over time. Scale bars 20 lm
c
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3. Integrin expression on hESC-CM (before and after
transplantation) largely matches the matrix type they
encounter or secrete in vivo.
4. Co-transplantation of hESC-EC with hESC-CM can
result in the formation of functional capillaries which
improves blood supply to the grafts.
5. hESC-CM can survive and mature in vivo for at least
24 weeks.
While the extracellular matrix present around hESC-CM
beating areas can be secreted by hESC-CM or by other cell
types, the human matrix components we identified in grafts
of over 4 weeks are most likely produced by cardiomyo-
cytes, since these make up over 90–99% of the grafts from
that time-point onwards [10, 28]. Collagen IV and some
fibronectin are secreted by adult cardiomyocytes, although
fibronectin is more prominent in the fetal heart [26]. Col-
lagen XVIII is associated with fetal myocardium only,
confirming the fetal-like phenotype of hESC-CM [18] even
though they mature significantly after transplantation. This
is also in agreement with our observation that fibronectin
secretion by hESC-CM is more pronounced at early time-
points and (like collagen XVIII) after myocardial infarc-
tion, when environmental factors upregulate expression of
fetal genes [31]. We cannot rule out the possibility that the
increased presence of these matrices is caused by slower
degradation in the infarcted heart, but this seems unlikely
considering the large time differences between the points
Fig. 3 Integrin expression on hESC-CM after transplantation.
a,f Expression of integrin a11 and b1 is unchanged. c,e Expression
of a3 is upregulated while a6 is slightly downregulated. b,d a5 and
aV are decreasingly expressed (see also Table 1). Grafts shown are
4 weeks (b,e) or 12 weeks (a,c,d,f) after transplantation. Scale bars
10 lm
Fig. 4 Extracellular matrix secretion from hESC-CM is increased
when transplanted into the infarcted heart. a Collagen I forms a large
part of the infarct and is present in even larger amounts around the
grafted hESC-CM. b Laminin forms part of the infarct and is present
in normal quantities around hESC-CM. c–f Human collagen IV
(c, overview in d) and human collagen XVIII (e, overview in f) are
secreted by hESC-CM and cover a considerable area around the graft.
g–h Laminin-211 forms part of the infarct and is present in normal
quantities around hESC-CM. i–j Fibronectin forms part of the infarct
and this is largely due to continuing secretion of human fibronectin by
hESC-CM. Scale bars (a–c,e,g–j) 20 lm, (d,f) 100 lm
c
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investigated and the shorter turnover time of fibronectin
and collagens, especially in myocardial infarction when
matrix metalloproteinases (MMPs) are abundantly present
[32]. In both non-infarcted and infarcted hearts, trans-
planted hESC-CM were surrounded by a substantial layer
of collagen I that was not cleared over time. Distant from
the grafts, the composition of the extracellular matrix in the
infarct zone was unaltered by the hESC-CM transplanta-
tion compared to previous reports [32–34]. Laminins were
not increased in the graft area, and thus the fibrotic tissue
separating donor from host cells consists of collagen I and
donor-derived collagen IV, collagen XVIII and, in the
infarcted heart, fibronectin.
Integrins expressed on HESC-CM mediate binding to
each of the matrices described, although we observed some
changes in their expression profile after transplantation.
The high expression of a11 is consistent with attachment to
collagens, and collagen synthesis by hESC-CM may be
essential for differentiation and proliferation, as described
for mouse ESC-CM and human fetal cardiomyocytes
[35, 36]. Although collagen XVIII is best known as a
precursor for endostatin [37], our observations indicate that
this collagen likely has a different function in hESC-CM
unrelated to inhibition of angiogenesis. Nevertheless, it
would be interesting to inhibit collagen XVIII production
in hESC-CM and to search for a potential effect on neo-
vascularization after myocardial infarction. Laminin-
binding integrins a3 and a6 were expressed at low levels by
only a few cells in vitro. After transplantation, however, a3
was markedly upregulated, becoming the principal lami-
nin-binding integrin, possibly together with a7 (which we
Fig. 5 Survival and continuing
maturation of transplanted
hESC-CM for at least 24 weeks.
a,b Immature hESC-CM in vitro
containing poorly organized
myofibrils and keratin threads;
black dots cytokeratin 8.
c–f hESC-CM grafts; black dots
GFP; d desmosome, n nucleus,
m myofibrils, hu human, ms
mouse, ECM extracellular
matrix. c Increased myofibril
content and organization and
desmosome formation in
hESC-CM 12 weeks after
transplantation. d Further
increased myofibril content and
organization and desmosome
formation in hESC-CM
24 weeks after transplantation.
e Extracellular matrix between
donor and host cardiomyocytes
24 weeks after transplantation.
f Overview of hESC-CM with
flanking hESC-derived
endothelial cells (ECs)
24 weeks after transplantation.
Scale bars (a–e) 200 nm,
(f) 1 lm
Fig. 6 Co-transplanted hESC-ECs form functional vessels in the host
myocardium. a Small clusters of GFP-expressing cells scattered
through the host myocardium 24 weeks after transplantation,
b–d Human endothelial cells forming capillaries in mouse myocar-
dium; black dots GFP, e erythrocyte, l leukocyte, n nucleus, EC
endothelial cell, hu human, ms mouse. e Overview of endothelial
structures in a beating area from hES3-GFP. f, g Ki-67-positive
endothelial cells expressing human PECAM and human von
Willebrand Factor. h Ki-67-positive hESC-derived endothelial
cells in a graft 12 weeks after transplantation. i,j Undifferentiated
hESCs; immunogold labeling for Tra-1-60 at the apical side (i)
and intracellular (j); black dots Tra-1-60; n nucleus. Scale bars
(a,e) 100 lm, (b,c) 1 lm (d) 500 nm (f,g) 20 lm (h,i) 200 nm
c
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could not quantify because of the lack of an acceptable
antibody). One reason for the excessive human fibronectin
secretion early after transplantation could be a response to
transforming growth factor b (TGFb), which is strongly
upregulated in the border zone in mice after myocardial
infarction and targets, amongst others, the fibronectin gene
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[38]. Fibronectin secretion could also be triggered by
suboptimal binding of transplanted hESC-CM to laminin;
at early time-points, fibronectin-binding integrins were
more prominently expressed than laminin-binding inte-
grins. Since laminin is not secreted in excess, modifying
hESC-CM to express more functional laminin-binding and
less fibronectin-binding integrins might help to reduce
extracellular matrix secretion by hESC-CM and accelerate
maturation [39, 40], provided their proliferative capacity
can be kept intact. Alternatively, co-injecting hESC-CM
with a mixture of the extracellular matrix proteins they
would otherwise secrete themselves might provide a more
gradual habituation of the donor cells and prevent part of
their matrix secretion.
Collagen I forms a layer around patches of grafted
hESC-CM, presumably a foreign body reaction by mouse
fibroblasts. To prevent this in future clinical applications, it
is essential that donor and host cells match as closely as
possible with regard to immunological, electrophysiologi-
cal, and mechanical characteristics (such as stiffness), since
fibroblasts ‘‘sense’’ discrepancies and respond by produc-
ing more extracellular matrix [41]. Other options may
include upregulating MMP secretion by hESC-CM, co-
injecting MMPs, or co-injecting inhibitors of tissue inhib-
itors of metalloproteinases (TIMPs). However, these
interventions need to be accurately timed and dosed, since
an excess of particular MMPs results in adverse remodel-
ing, such as dilatation [32, 42].
Although the excessive deposition of extracellular
matrix around intramyocardial grafts needs to be resolved
for electrophysiological reasons, it appears that oxygen and
nutrient supply to the grafts was established, since survival
and ultra-structural maturation were sustained over pro-
longed periods of 24 weeks. Contributing to this was the
co-injection of hESC-EC leading to the formation of
functional human capillaries connected to the mouse vas-
culature. Mouse ESC-EC and hESC-EC differentiation
have been described before [43, 44], and mouse ESC-EC
increased cardiac function in a mouse model of myocardial
infarction [43]. HESC-EC could be selected based on
expression of PECAM-1 on their surface. However, co-
injection of hESC-CM and hESC-EC has not been inves-
tigated to date. With improved selection methods for
obtaining pure populations of hESC-CM [45], defined co-
transplantation of hESC-CM and hESC-EC has now
become a realistic possibility that warrants further explo-
ration for eventual clinical application.
One limitation of our study is the interspecies difference
that may prevent functional coupling of donor and host
cardiomyocytes, since human cardiomyocytes are unlikely
to sustain prolonged periods of relative tachycardia in a
mouse heart which beats approximately 500 times per
minute. However, the long term survival, maturation, and
functional benefits of hESC-CM in this and other rodent in
vivo models [5, 10] suggests that most other factors are
likely to be similar in mouse and human hearts. Impor-
tantly, extracellular matrix response after injury in the
mouse heart is representative of that seen in the clinical
setting, when taking into account that the time course of
events is accelerated in mice [34]. Another reason for
choosing the mouse as a model system is the availability of
NOD-SCID mice, in which the influence of specific
immune reactions that might otherwise confound results
are reduced. Nevertheless, these experiments eventually
need to be repeated isogenically in larger animals, perhaps
using induced pluripotent stem (iPS) cells. IPS cells appear
to behave much the same as ESCs [46] and have now been
derived from species like porcine [47] for which ESCs are
not available.
In conclusion, both donor and host cells contribute to
excessive extracellular matrix formation after transplanta-
tion of hESC-CM into the mouse myocardium, and the
donor reaction is more pronounced in the presence of
myocardial infarction. Nevertheless, hESC-CM are able to
survive and mature after transplantation for prolonged
periods of at least 24 weeks, which may be supported by
donor-derived capillary formation from co-transplanted
hESC-EC. These results form the basis of future develop-
ments aiming to reduce the adverse fibrotic reaction that
currently complicates cell-based therapies for cardiac dis-
ease, and provide additional clues for improving successful
engraftment of hESC-CM, and cardiomyocytes in general,
by co-transplanting endothelial cells.
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